NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) is expected to announce its Q3 2026 results on Friday, November 13th. Analysts expect the company to announce earnings of ($0.2134) per share and revenue of $1.28 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 16, 2026 at 8:30 AM ET.
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million. On average, analysts expect NRx Pharmaceuticals to post ($1.14) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.
NRx Pharmaceuticals Price Performance
NRXP opened at $2.36 on Wednesday. The company has a market cap of $103.01 million, a price-to-earnings ratio of -4.29 and a beta of 2.11. The firm has a 50 day simple moving average of $2.89 and a 200 day simple moving average of $2.96. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05.
Wall Street Analysts Forecast Growth
A number of research firms have commented on NRXP. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of NRx Pharmaceuticals in a report on Monday, September 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, November 3rd. UBS Group reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. Wall Street Zen lowered NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Wolfe Research began coverage on NRx Pharmaceuticals in a research report on Thursday, October 15th. They issued an “outperform” rating on the stock. Six investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.
Read Our Latest Report on NRXP
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset. NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.
Read More
- Five stocks we like better than NRx Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
